Early bactericidal activity of antituberculosis agents

Antituberculosis Chemotherapy

Volumn 10, Issue , 2011, Pages 213-219

  Diacon, Andreas H ^a   Stefan Maritz, J ^a   Donald, Peter R ^b  

^a SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893946385     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000324633     Document Type: Chapter

References (32)

1. Jindani A, Aber V, Edwards EA, Mitchison DA:The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121; 939-949.
2. Chan SL, Yew WW, Ma WK, Girling DJ, Aber VR, Felmingham D, Allen BW, Mitchison DA: The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis 1992;73:33-38.
3. Sirgel FA, Fourie PB, Donald PR, Padayatchi N, Rustomjee R, Levin J, Roscigno G, Norman J, McIlleron H, Mitchison DA, Rifapentine EBA Collaborative Study Group: The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005;172:128-135.
4. Peloquin CA: Therapeutic drug monitoring:principles and application in mycobacterial infections. Drug Ther 1992;22:31-36.
5. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H: Early bactericidal activity of high dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 2007;51:2994-2996.
6. Donald PR, Sirgel FA, Venter A, Parkin DP, Seifart HI, van de Wal BW, Werely C, van Helden PD, Maritz JS: The influence of human Nacetyltransferase genotype on the early bactericidal activity of isoniazid. Clin Infect Dis 2004;39:1425-1430.
7. Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, Sirgel FA, Venter A, Maritz JS: The influence of dose and Nacetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007;63:633-639.
8. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R: Early and extended bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-612.
9. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V: A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-227.
10. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, de Marez T, van Heeswijk R, Kerstens R, Koul A, de Beule K, Donald PR, McNeeley DF: Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-2835.
11. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW, Ginsberg AM, Spigelman MK: Early bactericidal activity and pharmacokinetics of PA-824 in smearpositive tuberculosis patients. Antimicrob Agents Chemother 2010;54:3402-3407.
12. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M: OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006;3:e466.
13. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells C, Paccaly AJ, Donald PR: Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis, in press.
14. Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, Palaci M, Johnson JL:Early and extended bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178:1180-1185.
15. Anargyros P, Astill DSJ, Lim ISL: Comparison of improved BACTEC and Lowenstein-Jensen media for culture of mycobacteria from clinical specimens. J Clin Microbiol 1990;28:1288-1291.
16. Abe C, Hosojima S, Fukasawa Y, Kazumi Y, Takahashi M, Hirano K, Mori T: Comparison of MB-Check BACTEC and egg-based media for recovery of mycobacteria. J Clin Micobiol 1992;30:878-881.
17. Badak FZ, Kiska DL, Setterquist S, Hartley C, O'Connel MA, Hopfer RL: Comparison of mycobacteria growth indicator tube with BACTEC 460 for detection and recovery of mycobacteria from clinical specimens. J Clin Microbiol 1996;34:2236-2239.
18. Pfyffer GE, Wlescher H-M, Kissling P, Cieslak C, Casal MJ, Gutierrez J, Rüsch-Gerdes S: Comparison of the mycobacteria growth indicator tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Microbiol 1997;35:364-368.
19. Chew WK, Lasaitis RM, Schio FA, Gilbert GL:Clinical evaluation of the mycobacterial growth indicator tube (MGIT) compared with radiometric (BACTEC) and solid media for isolation of Mycobacterium species. J Med Microbiol 1998;47:821-827.
20. Somskövi Á, Magyar P: Comparison of the mycobacteria growth indicator tube with MB Redox, Löwenstein-Jensen and Mddlebrook 7H11 media for recovery of mycobacteria in clinical specimens. J Clin Microbiol 1999;37:1366-1369.
21. Hesseling AC, Walzl G, Enarson DA, Carroll NM, Duncan K, Lukey PT, Lombard C, Donald PR, Lawrence KA, Gie RP, van Helden PD, Beyers N: Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis 2010;14:560-570.
22. Epstein MD, Schluger NW, Davidow AL, Bonk S, Rom WN, Hanna B: Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 1998;113:379-386.
23. Pheiffer C, Carrol NM, Beyers N, Donald P, Duncan K, Uys P, van Helden P: Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis 2008;12:792-798.
24. Mitchison DA: Basic mechanisms of chemotherapy. Chest 1979;76(suppl): 771-781.
25. Wayne LG, Hayes LG: An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996;64:2062-2069.
26. Mitchison DA, Coates ARM: Predictive in vitro models of the sterilizing activity of antituberculosis drugs. Curr Pharm Des 2004;10:3285-3295.
27. Dhillon J, Lowrie DB, Mitchison DA: Mycobacterium tuberculosis from chronic murine infection grows in liquid but not on solid media. BMC Infect Dis 2004;4:51.
28. Diacon AH, Maritz JS, Venter A, van Helden PD, Andries K, McNeeley DF, Donald PR: Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Microbiol Clin Med 2010;29:1561-1565.
29. Kennedy N, Gillespie SH, Saruni AOS, Kisyombe G, McNerney R, Ngowi FI, Wilson S: Polymerase chain reaction for assessing treatment response in patients with pulmonary tuberculosis. J Infect Dis 1994;170:713-716.
30. Desjardin LE, Perkins MD, Wolski K, Haun S, Teixeira L, Chen Y, Johnson JL, Ellner JJ, Dietze R, Bates J, Cave D, Eisenach KD: Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 1999;160:203-210.
31. Li L, Mahan CS, Palaci M, Horter L, Loeffelholz L, Johnson JL, Dietze R, Debanne SM, Joloba ML, Okwera A, Boom WH, Eisenach KD: Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J Clin Microbiol 2010;48:46-51.
32. Wallis RS, Phillips M, Johnson JL, Teixeira L, Rocha LM, Maciel E, Rose L, Wells C, Palaci M, Dietze R, Eisenach K, Ellner JJ: Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials. Antimicrob Agents Chemother 2001;45:1302-1304.